| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/18/2001 | US6290978 Derivatives of arabinogalactan and compositions including the same |
| 09/18/2001 | US6290974 Complex comprising beta-lactoglobulin (purified by bioselective absorption to an immobilized affinity ligand) and vitamin a, vitamin d, vitamin e, vitamin k1, cholesterol, or conjugated linoleic acid; food additive |
| 09/18/2001 | US6290970 Transferrin receptor protein of Moraxella |
| 09/18/2001 | US6290967 Stabilizers for lyophilized vaccines |
| 09/18/2001 | US6290960 Vaccine and antitoxin for the treatment of C. difficile disease |
| 09/18/2001 | US6290955 Antibodies against T cells as therapeutics |
| 09/18/2001 | US6290953 May be a conjugate which includes a targeting portion adapted to target the conjugate to a specific cell type or anatomical location. |
| 09/18/2001 | US6290930 Cosolvent, especially ethanol, present in an amount that dissolves or solubilizes the budesonide in the mixture of cosolvent and propellant. |
| 09/18/2001 | CA2735316A1 Thrombin preparations and process for their production |
| 09/18/2001 | CA2231118C Pharmaceutical preparation containing nimesulide for topical use |
| 09/18/2001 | CA2168364C Stabilized pharmaceutical composition containing bupropion |
| 09/18/2001 | CA2139133C Solid and liquid solutions of drugs which ar not readily soluble in water |
| 09/14/2001 | CA2340549A1 Use of a methoxysalicylaldehyde derivative for stabilizing a solid-state protein |
| 09/13/2001 | WO2001067105A1 Carriers coated with polysaccharides, their preparation and use |
| 09/13/2001 | WO2001066772A2 Heparinase iii and uses thereof |
| 09/13/2001 | WO2001066700A1 Transcutaneous immunization for large particulate antigens |
| 09/13/2001 | WO2001066601A1 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |
| 09/13/2001 | WO2001066550A2 Compounds for pdt |
| 09/13/2001 | WO2001066241A1 Microcapsules - vi |
| 09/13/2001 | WO2001066240A1 Skincare agents |
| 09/13/2001 | WO2001066214A1 Methods for extraction and reaction using supercritical fluids |
| 09/13/2001 | WO2001066164A1 Modified protein matrices |
| 09/13/2001 | WO2001066159A1 Novel natural polymer-based material with improved properties for use in human and veterinary medicine and the method of manufacturing such |
| 09/13/2001 | WO2001066149A2 Nucleic acid formulations for gene delivery and methods of use |
| 09/13/2001 | WO2001066148A1 A method of sensitising endothelial cells to prodrugs |
| 09/13/2001 | WO2001066147A2 Antimicrobial compounds and formulations |
| 09/13/2001 | WO2001066145A1 Anti-infective active substance combinations and the use thereof for the topical treatment of fungus diseases of toe and finger nails |
| 09/13/2001 | WO2001066137A1 Adenovirus formulations |
| 09/13/2001 | WO2001066132A2 Hiv immune adjuvant therapy |
| 09/13/2001 | WO2001066121A1 Oleoresin of hypericum perforatum l., method for obtaining said oleoresin and the use thereof |
| 09/13/2001 | WO2001066115A2 Acetylsalicylic acid solutions |
| 09/13/2001 | WO2001066093A2 Sustained release ranolazine formulations |
| 09/13/2001 | WO2001066091A1 Method of preparing solid dispersions |
| 09/13/2001 | WO2001066089A2 Pharmaceutical compositions comprising cannabis |
| 09/13/2001 | WO2001066088A1 New self emulsifying drug delivery system |
| 09/13/2001 | WO2001066087A1 New self emulsifying drug delivery system |
| 09/13/2001 | WO2001066086A1 Lipid carrier |
| 09/13/2001 | WO2001066085A2 Micellar pharmaceutical compositions for buccal and pulmonary application |
| 09/13/2001 | WO2001066084A2 Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa |
| 09/13/2001 | WO2001066081A2 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 09/13/2001 | WO2001066053A1 Colored visco-elastic composition |
| 09/13/2001 | WO2001066017A1 Biocompatible material composition adaptable to diverse therapeutic indications |
| 09/13/2001 | WO2001066016A1 Embolic agents visible under ultrasound |
| 09/13/2001 | WO2001065911A2 Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| 09/13/2001 | WO2001028492A3 Polyanhydrides with biologically active degradation products |
| 09/13/2001 | WO2001026635A3 Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| 09/13/2001 | WO2001015734A3 High viscosity liquid controlled delivery system and medical or surgical device |
| 09/13/2001 | WO2001015671A3 Flushable disposable polymeric products |
| 09/13/2001 | WO2001013906A3 Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| 09/13/2001 | WO2001009000B1 A device for spray dispensing a composition for topical application comprising vitamin e and essential fatty acids |
| 09/13/2001 | WO2000053191A3 Modulation of skeletal muscle precursor cell activation |
| 09/13/2001 | WO1997042968A3 Administration of histamine for therapeutic purposes |
| 09/13/2001 | US20010021763 Coupling; drug delivery |
| 09/13/2001 | US20010021758 Drugs, medical diagnosis |
| 09/13/2001 | US20010021721 Storage stability |
| 09/13/2001 | US20010021703 Crosslinking the micelle components to completely entrap the drug until it is delivered to the site of action; nondiffusing |
| 09/13/2001 | US20010021694 Treating bulimia and eating disorders, stimulating cholecystokinin, protein powder with glycomacropeptide or casein, fatty acid, fiber |
| 09/13/2001 | US20010021693 Non-aqueous or oily injection formulation obtainable by in-situ preparation and stabilization of the free, unstable base of valnemulin; treating infectious diseases in livestock and domestic animals; storage stability |
| 09/13/2001 | US20010021392 Such as ibuprofen |
| 09/13/2001 | US20010021390 Mixture containing cetylpyridium chloride |
| 09/13/2001 | US20010021385 Human papillomavirus vaccine with disassembled and reassembled virus-like particles |
| 09/13/2001 | DE10011081A1 Lacquer formulation for treating and preventing onychomycosis, comprising combination of systemic and topical antimycotic agents in film-forming polymer base |
| 09/13/2001 | DE10011032A1 Stable solutions of acetylsalicylic acid in mixture of organic solvent and water, useful for topical treatment of pain, especially pain associated with herpes zoster |
| 09/13/2001 | DE10010509A1 Oral pharmaceutical formulations with controllable release characteristics, e.g. rapid or delayed release, contain sucrose fatty acid ester as drug release controlling agent |
| 09/13/2001 | DE10010264A1 Production of nano- or micro-capsules used in the production of liposomes coated with polyelectrolytes comprises electrically recharging template particles with polyelectrolytes |
| 09/13/2001 | CA2799545A1 Adenovirus formulations |
| 09/13/2001 | CA2402433A1 Compounds for pdt |
| 09/13/2001 | CA2402027A1 A method of sensitising endothelial cells to prodrugs |
| 09/13/2001 | CA2402024A1 Hiv immune adjuvant therapy |
| 09/13/2001 | CA2401889A1 Lipid carrier |
| 09/13/2001 | CA2401879A1 Embolic agents visible under ultrasound |
| 09/13/2001 | CA2401857A1 New self emulsifying drug delivery system |
| 09/13/2001 | CA2401327A1 Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use |
| 09/13/2001 | CA2401239A1 Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| 09/13/2001 | CA2400410A1 Antimicrobial compounds and formulations |
| 09/13/2001 | CA2400401A1 Novel natural polymer-based material with improved properties for use in human and veterinary medicine and the method of manufacturing such |
| 09/13/2001 | CA2372931A1 Oleoresin of hypericum perforatum l., method for obtaining said oleoresin and the use thereof |
| 09/12/2001 | EP1132395A2 Process for the preparation of a pharmacologically active peptide |
| 09/12/2001 | EP1132097A2 Cellular and serum protein anchors and conjugates |
| 09/12/2001 | EP1132096A1 Suppositories |
| 09/12/2001 | EP1132095A1 Fatty acid-silicate polymer containing composition |
| 09/12/2001 | EP1132094A1 Percutaneously administrable preparations containing cerebral function activators |
| 09/12/2001 | EP1132089A1 Extract from loquat seeds against fibrosis |
| 09/12/2001 | EP1132080A2 Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
| 09/12/2001 | EP1132065A1 Coloured visco-elastic composition |
| 09/12/2001 | EP1131633A2 Hiv-specific t-cell induction |
| 09/12/2001 | EP1131457A1 Systemic viral/ligand gene delivery system and gene therapy |
| 09/12/2001 | EP1131344A2 Retro-inversion peptides that target git transport receptors and related methods |
| 09/12/2001 | EP1131340A2 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 09/12/2001 | EP1131327A1 Prostaglandin conjugates for treating or preventing bone disease |
| 09/12/2001 | EP1131106A1 Compositions and methods for producing vascular occlusion |
| 09/12/2001 | EP1131104A1 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
| 09/12/2001 | EP1131103A1 Stable amorphous amifostine compositions and methods for the preparation and use of same |
| 09/12/2001 | EP1131100A2 Therapeutic compositions for metabolic bone disorders or bone metastases |
| 09/12/2001 | EP1131089A1 Stable aqueous insulin preparations without phenol and cresol |
| 09/12/2001 | EP1131072A2 Pharmaceutical combination preparations of carvedilol and hydrochlorothiazide |
| 09/12/2001 | EP1131071A1 Nicotine-containing pharmaceutical compositions giving a rapid transmucosal absorption |
| 09/12/2001 | EP1131070A1 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| 09/12/2001 | EP1131068A1 Compositions of and process for producing isotretinoin having low particle size |
| 09/12/2001 | EP1131065A2 Utilisation of dialkylfumarates |